Project Grant K24HL179901
Award Date 9/15/25
Completion Date 8/31/30
Dollars Obligated $133K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The federal Project Grant award of $676,748.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to extend neutrophil survival in neutropenia-related pneumonia. The goal is to explore an alternative strategy for treating and preventing neutropenia-related pneumonia by increasing the lifespan of neutrophils in the lungs of neutropenic patients. Specifically, the research will investigate the role and regulation of gasdermin D...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000.00 in funding to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) to develop methodologies for revealing the role of the blood microbiome in the gut-lung axis for asthma pathogenesis. The key products and services to be delivered include: A strain-resolved computational pipeline for reduced metagenomic sequencing to...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $189,000 Project Grant under CFDA #93.837 Cardiovascular Diseases Research program to the University of Colorado-Denver. The 2-year grant, with a period of performance from September 15, 2025 to August 31, 2027, will support research to investigate the role of outdoor air pollution and environmental allergens in driving treatment response in children with acute asthma...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), is funding a research project titled "Emulating Hypothetical Target Trials to Establish the Comparative Effectiveness of Biologics in Asthma." The $834,840 award to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, supports research to generate evidence on the comparative effectiveness of biologic...
- This $680,562 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the long-term lung epithelial alterations resulting from early-life respiratory syncytial virus (RSV) infection. The research aims to determine the mechanisms by which early-life RSV infection predisposes individuals to developing asthma later in life, focusing on the role of innate cytokines like IL-1β and IL-33 in driving...
- This $800,962 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Brigham & Women's Hospital on the molecular mechanisms regulating fibroproliferative pulmonary vasculopathy in early pulmonary arterial hypertension (PAH). The research aims to investigate the role of the c-terminal Src kinase (CSK) and its regulation of Src kinase activation in the context of endothelial dysfunction and fibrosis,...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $818,279 to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on improving the subtyping and characterization of obstructive sleep apnea (OSA). The project will leverage data from existing research cohorts and a clinical biobank to quantify the reproducibility of OSA severity markers and derive physiologically...
- This federal Project Grant award of $710,302 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program aims to investigate the origin and characterize the functional state of the lung interstitial neutrophil (LIN) subset. The project seeks to advance the understanding of the function, fate, pathophysiological role, and origin of LINs, and explore their therapeutic potential. The research will be conducted by Brigham & Women's...
- This $131,783 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will fund a study to develop and implement a protocol for biospecimen collections before and after bronchoscopic lung volume reduction (BLVR) procedures in COPD patients. The goal is to identify blood and bronchoalveolar lavage fluid biomarkers associated with COPD phenotypes...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $260,445 to Brigham & Women's Hospital Inc. to conduct research on identifying biomarkers associated with nasal polyp recurrence in patients with aspirin-exacerbated respiratory disease (AERD). The key objectives are to: 1) Establish a biomarker-based predictive model for nasal polyp recurrence in AERD patients,...